NCT06495281已完成不适用
A Observational Study to Evaluate Effectiveness, Safety of Triple Combination Therapy of Zemidapa and Metformin in Patients With Type 2 DM Who Received Double or Triple Combination Therapy Including DPP4-inhibitor Other Than Gemigliptin
LG Chem1 个研究点 分布在 1 个国家目标入组 2,044 人开始时间: 2023年10月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2,044
- 试验地点
- 1
- 主要终点
- change from baseline of HbA1c at 12 weeks
研究概览
简要总结
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •type 2 DM Patients who are receiving one of the following three therapies during which the patients are prescribed with Zemidapa Tab. for the first time at the discretion of the attending physician:
- •Double combination therapy (Metformin and a DPP-4 inhibitor other than Gemigliptin)
- •Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and a SGLT-2 inhibitor)
- •Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and Sulfonylurea [SU])
- •patients with HbA1c results and who signed the written consent form
排除标准
- •- Patients contraindicated for the approved use of Zemidapa Tab. or have participated in another clinical study within 12 weeks
结局指标
主要结局
change from baseline of HbA1c at 12 weeks
时间窗: baseline, 12 weeks
次要结局
- the rate of subjects who reached the target value of less than 7% HbA1c(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisNASHNCT05327127Kowa Research Institute, Inc.228
终止
3 期
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CHepatitis CNCT01500772Debiopharm International SA6
已完成
3 期
Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus PatientsType2 DiabetesNCT06329674AJU Pharm Co., Ltd.235
已完成
3 期
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT01241240Allergan192
已完成
3 期
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT01217606Allergan185